[The Daily Vox] HANEEFA BEGUM, 40, from Kashmir’s Ashmuqam slowly watches her 10-year-old son, Arshid Bhat, going into the lap of death. He has been diagnosed with acute leukaemia. A mother of five daughters and the only son, the family has little means to save him. Haneefa shares the struggle of saving her son with The Daily Vox.

Related Links:

Publication date: Available online 11 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jianai Sun, Jingjing Zhu, De Zhou, Lixia Zhu, Xiudi Yang, Mixue Xie, Li Li, Xianbo Huang, Mingyu Zhu, Yanlong Zheng, Wanzhuo Xie, Xiujin YeAbstractIn this retrospective data analysis of 288 newly diagnosed adult acute promyelocytic leukemia patients in Hangzhou, China, we report an early death rate of 5.9% (17/288 patients). The median follow-up time was 32 months (6–78 months), and the 3-year disease-free survival (DFS) and overall survival (OS) rates were 90.83% and 91.69%, respectively. In the multivariable an…

No abstract available

Source: Oncology TimesCategory: Cancer & Oncology Tags: News Source Type: research

Authors: Horowitz NA, Akasha D, Rowe JM
Abstract
INTRODUCTION: Acute lymphoblastic leukemia (ALL) is a clonal disease of the hematopoietic system characterized by unique genetic characteristics. The significance of these genetic features has evolved over the past three decades. In the 1980s and 1990s the primary interest was in excluding the Philadelphia chromosome; a finding more common in older adults which uniformly predicted for a rapidly fatal outcome. Areas covered: Over the past 15 years, much has evolved. Tyrosine kinase inhibitors completely changed the prognosis of Ph-positive ALL. In addition, the geneti…

Cytarabine (ara-C) is a well-established agent widely used for treating AML. Conventionally, it is combined with anthracyclines for treating newly diagnosed Acute Myeloid Leukaemia (AML). At higher doses it is combined with the purine analogue fludarabine plus idarubicin and G-CSF (FLAG-Ida) for the treatment of relapsed or refractory AML. Fludarabine is known to potentiate intracellular accumulation of the active cytotoxic metabolite ara-CTP from ara-C via inhibition of ribonucleotide reductase and the normal formation of endogenous dCTP [1], and removal of the inhibition of deoxycytidine kinase (dCK) by dCTP [2,3].

Source: Leukemia ResearchCategory: Hematology Authors: Source Type: research

This study accessed the extent of contact system activation, the levels of extracellular traps, and coagulation activation in hematologic malignancies including acute leukemia. In 154 patients with hematologic malignancies (acute leukemia,n = 29; myelodysplastic syndrome,n = 20; myeloproliferative neoplasms,n = 69; plasma cell myeloma,n = 36) and 48 normal controls, the levels of coagulation factors (fibrinogen and factor VII, VIII, IX, and XII), D-dimer, thrombin generation, extracellular trap markers (histone–DNA complex, cell-free dsDNA, leukocyte elastase), …

In this retrospective data analysis of 288 newly diagnosed adult acute promyelocytic leukemia patients in Hangzhou, China, we report an early death rate of 5.9% (17/288 patients). The median follow-up time was 32 months (6 –78 months), and the 3-year disease-free survival (DFS) and overall survival (OS) rates were 90.83% and 91.69%, respectively. In the multivariable analysis, older age (≥60 yrs) was the only independent risk factor for ED (hazard ratio [HR] 15.057; P=0.004). High white blood cell count was not a risk factor for early death (P=0.055), but for relapse (HR 2.7, P= 0.009).

Source: Clinical Lymphoma, Myeloma and LeukemiaCategory: Hematology Authors: Tags: Original Study Source Type: research

Conditions:   Philadelphia Chromosome Positive Acute Lymphocytic Leukemia;   Tyrosine Kinase Inhibitor;   Minimal Residual Disease;   Allogeneic Hematopoietic Stem Cell Transplantation Intervention:   Drug: Tyrosine kinase inhibitor (TKIs) Sponsors:   Nanfang Hospital of Southern Medical University;   Peking University People’s Hospital;   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;   Guangzhou First People’s Hospital;   Zhujiang Hospital;   Third Affil…

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Condition:   Acute Promyelocytic Leukemia Intervention:   Drug: Arsenic Trioxide Sponsor:   The University of Hong Kong Recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Condition:   Acute Myeloid Leukemia (AML) Interventions:   Drug: Venetoclax;   Drug: Gilteritinib Sponsors:   AbbVie;   Astellas Pharma Inc;   Genentech, Inc. Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Conditions:   Philadelphia Chromosome Positive Acute Lymphocytic Leukemia;   Tyrosine Kinase Inhibitor;   Minimal Residual Disease;   Allogeneic Hematopoietic Stem Cell Transplantation Intervention:   Drug: Tyrosine kinase inhibitor (TKIs) Sponsors:   Nanfang Hospital of Southern Medical University;   Peking University People’s Hospital;   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;   Guangzhou First People’s Hospital;   Zhujiang Hospital;   Third Affil…

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image